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Summary
In type 1 diabetes (T1D), autoreactive cytotoxic CD8+ T cells are impli-
cated in the destruction of insulin-producing β cells. The HLA-B*3906 
and HLA-A*2402 class I genes confer increased risk and promote early 
disease onset, suggesting that CD8+ T cells that recognize peptides pre-
sented by these class I molecules on pancreatic β cells play a pivotal role 
in the autoimmune response. We examined the frequency and phenotype 
of circulating preproinsulin (PPI)-specific and insulin B (InsB)-specific 
CD8+ T cells in HLA-B*3906+ children newly diagnosed with T1D and 
in high-risk HLA-A*2402+ children before the appearance of disease-specific 
autoantibodies and before diagnosis of T1D. Antigen-specific CD8+ T cells 
were detected using human leucocyte antigen (HLA) class I tetramers and 
flow cytometry was used to assess memory status. In HLA-B*3906+ children 
with T1D, we observed an increase in PPI5–12-specific transitional memory 
CD8+ T cells compared to non-diabetic, age- and HLA-matched subjects. 
Furthermore, PPI5–12-specific CD8+ T cells in HLA-B*3906+ children with 
T1D showed a significantly more antigen-experienced phenotype compared 
to polyclonal CD8+ T cells. In longitudinal samples from high-risk HLA-
A*2402+ children, the percentage of terminal effector cells within the 
InsB15–24-specific CD8+ T cells was increased before diagnosis relative to 
samples taken before the appearance of autoantibodies. This is the first 
study, to our knowledge, to report HLA-B*3906-restricted autoreactive CD8+ 
T cells in T1D. Collectively, our results provide evidence that β cell-reactive 
CD8+ T cells restricted by disease-associated HLA class I molecules display 
an antigen-experienced phenotype and acquire enhanced effector function 
during the period leading to clinical diagnosis, implicating these cells in 
driving disease.
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Introduction
Type 1 diabetes is an autoimmune disease in which insulin-
secreting β cells of the pancreatic islets are selectively 
destroyed [1,2]. Several lines of evidence point to CD8+ 
cytotoxic T cells as critical players in β cell destruction. 
Firstly, CD8+ T cells are the dominant cell type found in 
insulitic lesions in the pancreas of patients with type 1 
diabetes [3–5], and hyperexpression of human leucocyte 
antigen (HLA) class I molecules in this lesion has the 
potential to enhance peptide presentation to infiltrating 
CD8+ T cells [3–8]. Secondly, CD8+ T cells with specificity 
for β cell antigens are present in the blood and islets of 
individuals with type 1 diabetes [9–14]. Thirdly, CD8+ T 
cell clones recognizing β cell epitopes are able to kill 
isolated β cells in vitro, exemplifying the potential for 
CD8+ T cells to constitute major effectors of β cell death 
[13,15]. Lastly, recent success in delaying β cell loss using 
immunotherapy targeted at effector CD8+ T cells suggests 
that CD8+ T cells are a dominant killing pathway [16].
These immunological observations associate the CD8+ 
T cell pathway with disease, a proposal that is further 
supported by genetic studies. These highlight specific HLA 
class I loci with type 1 diabetes predisposition indepen-
dently of linkage disequilibrium with HLA class II [17]. 
For example, HLA-B*39 was identified as a major genetic 
risk locus in a large-scale study of single nucleotide poly-
morphisms associated with allelic forms of HLA class I 
genes [17]. HLA-B*39 is relatively rare, being present in 
0·5–1·2% of European, North American and Australian 
populations and 0·1% of Southeast Asian populations 
[18,19]. HLA-B*39 polymorphism is associated with 
increased susceptibility to type 1 diabetes, providing an 
odds ratio of 2·41 in a case–control set, and a relative 
risk of 3·55 in affected sibling-pair families [17]. In addi-
tion, HLA-B*39 polymorphism associates with a lower age 
of type 1 diabetes diagnosis, and the HLA-B*3906 subtype 
is linked to a lower age of diagnosis by an average of 
1·7–3·7 years in several independent studies [17,20–24]. 
HLA-B*39 polymorphism is also associated with acceler-
ated disease progression in children from the point of 
autoantibody development to clinical diagnosis, implying 
more rapid β cell destruction [25,26]. Furthermore, the 
HLA-B*3906 variant significantly enhances the risk of type 
1 diabetes in individuals carrying specific HLA-DR/DQ 
haplotypes; namely, DRB01*0404-DQB1*0302 [21,23,26–29] 
and DRB1*08–DQB1*0402 [24,29–31].
At the HLA-A locus, the HLA-A*24 allele has a strong 
type 1 diabetes disease-predisposing effect. The HLA-A*24 
supertype is present in 12–20% of Caucasian and 60% 
of Japanese populations, with HLA-A*2402 being the most 
common variant [32,33]. Polymorphisms associated with 
the HLA-A*24 allele confer a higher disease risk, with an 
odds ratio of 1·5 [17], and share disease-influencing 
features in common with HLA-B*39. For example, HLA-
A*24 is significantly associated with a younger age at 
diagnosis [17,34–36]. HLA-A*24 polymorphisms are an 
independent predictor of progression to type 1 diabetes 
in autoantibody-positive first-degree relatives of individuals 
with type 1 diabetes [37] and are associated with acceler-
ated disease progression from seroconversion to clinical 
diagnosis [26,37–39]. Furthermore, the presence of HLA-
A*24 has been associated with early and complete β cell 
destruction after diagnosis [40,41], and with poor functional 
outcome in islet transplant recipients [42].
Collectively, these studies prompt questions in relation 
to the presentation of β cell autoantigens to CD8+ T cells 
by HLA-B*39- and HLA-A*24-encoded HLA class I mol-
ecules and the potential of these events to drive β cell 
destruction and accelerate type 1 diabetes progression. We 
recently identified preproinsulin epitopes naturally pro-
cessed and presented by HLA class I molecules encoded 
by HLA-B*3906 and HLA-A*2402 and associated with 
disease risk and progression [43,44]. In the present study, 
we used this insight to examine the repertoires of HLA-
B*3906- and HLA-A*2402-restricted β cell-specific CD8+ 
T cells in children with, or at risk of, type 1 diabetes. We 
analysed samples from Finnish cohorts in which the inde-
pendent and additive effects of these high-risk alleles on 
type 1 diabetes risk are well documented [21,23,26,27,29]. 
We provide evidence that autoreactive CD8+ T cells 
restricted by HLA-B*3906 and HLA-A*2402-encoded HLA 
class I molecules display an antigen-experienced phenotype 
and acquire enhanced effector function during the period 
leading to clinical diagnosis of type 1 diabetes.
Materials and methods
Subjects
The HLA-B*3906+ study cohort comprised 10 children 
with newly diagnosed type 1 diabetes (time after clinical 
diagnosis 2–10  days; median age 2·7  years) and seven 
non-diabetic children recruited as control subjects, with 
a median age of 2·2 years (Table 1). Additionally, one 
child had blood drawn at the age of 3·3 years, 5 years 
before   she was diagnosed with   type 1 diabetes at the 
age of  8·6 years. All children with newly diagnosed type 
1 diabetes were recruited from the Finnish Pediatric 
Diabetes Register [45]. The Finnish Pediatric Diabetes 
Register study was approved by the Ethical Committee 
of the Hospital District of Helsinki and Uusimaa and 
the register steering committee. The parents of the chil-
dren gave their written informed consent. Five control 
subjects were healthy siblings of type 1 diabetes-affected 
children recruited from the Finnish Pediatric Diabetes 
Register, and two control subjects had HLA class II 
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genotypes associated with increased risk for type 1 dia-
betes and were recruited as participants in the Finnish 
Type 1 Diabetes Prediction and Prevention (DIPP) study 
[46,47]. Six of seven control subjects were autoantibody-
negative at the time of blood draw. Although one of 
the seven control subjects was positive for insulin autoan-
tibodies (IAA) this subject was included, as it known 
that the number of detectable autoantibodies is related 
to risk of progression to type 1 diabetes, with seroposi-
tivity for two or more islet autoantibodies conferring 
high risk for developing type 1 diabetes, whereas posi-
tivity for a single autoantibody may represent non-
progressive or regressive β cell autoimmunity [48]. The 
DIPP study was approved by local Ethics Committees 
and all families participating in the study provided writ-
ten informed consent.
The HLA-A*2402+ study cohort comprised 15 children 
sampled before diagnosis of type 1 diabetes (median time 
before clinical diagnosis  =  7  months; median age  =  5·0 
years) and 15 autoantibody-negative non-diabetic children 
recruited as control subjects, with a median age of 4·9 years 
(Table 2). Of the 15 children who provided samples before 
diagnosis of type 1 diabetes, 11 had blood drawn before 
seroconversion to autoantibody positivity (median time 
before seroconversion = 5 months; median age = 1·5 years) 
(Table 3). All HLA-A*2402+ study subjects participated in 
the DIPP study with regular follow-up and had HLA class 
II genotypes associated with increased risk for type 1 
diabetes [49]. Positivity for islet autoantibodies was ana-
lysed in all subjects participating in either the Finnish 
Pediatric Diabetes Register or the DIPP study at the time 
of sampling, as previously described [46,50]. Positivity for 
Epstein–Barr virus (EBV) immunoglobulin (Ig)G antibodies 
was analysed in 12 of 15 subjects whose samples were 
stained with EBV tetramers. Serum samples were tested 
for anti-viral capsid antigen (VCA) and anti-early antigen 
(EA) IgG using an automated immunoanalyzer based on 
enzyme-linked fluorescence (ELFA) technology (VIDAS®; 
bioMérieux, Marcy l’Etoile, France). Results were reported 
as negative or positive with cut-offs of 0·1 and 0·23 test 
value.
Tetramer assembly
Soluble, fluorochrome-conjugated peptide-HLA class I 
tetramers were generated as described previously [51]. The 
peptide–human leucocyte antigen (pHLA)-B*3906 tetramers 
were manufactured with PPI5–12 test peptides [43] and EBV 
BMRF1268–276 control peptides [43,52]. The pHLA-A*2402 
tetramers were manufactured with PPI3–11 and InsB15–24 test 
peptides [13,53]. Epitope sequences are given in Table 4. 
Tetramers were assembled over five separate 20-min steps 
with the successive addition of streptavidin–allophycocyanin 
Table 1. HLA-B*3906+ subject information
  T1D subjects Controls
n 10 7
Sex n (%)
Male 6 (60%) 3 (43%)
Female 4 (40%) 4 (57%)
Age, median (IQR) (years) 2·7 (1·8–3·3) 2·2 (1·8–4·1)
Age at diagnosis, median (IQR) 
(years)
2·6 (1·8–3·3) n.a.
T1D duration (days) 5 (3–7) n.a.
Autoantibody-positive, n (%) 9 (90%) 1 (14%)
T1D = type 1 diabetes; IQR = interquartile range; n.a. = not available.
Table 2. HLA-A*2402+ subject information
  T1D subjects Controls
n 15 15
Sex n (%)
Male 10 (66%) 10 (66%)
Female 5 (33%) 5 (33%)
Age, median (IQR) (years) 5·0 (1·7–9·0) 4·9 (1·8–8·5)
Age at diagnosis, median (IQR) 
(years)
5·9 (3·5–9·3) n.a.
Time before diagnosis, median 
(IQR) (months)
7 (4–21) n.a.
Autoantibody-positive, n (%) 14 (93%) 0 (0%)
T1D = type 1 diabetes; IQR = interquartile range; n.a. = not available.









Male 9 (82%) 9 (82%)
Female 2 (18%) 2 (18%)
Age, median (IQR) 
(years)
1·5 (1·0–2·1) 5·8 (3·4–9·8)
Age at seroconversion, 
median (IQR) (years)
2·5 (1·3–3·2) 2·5 (1·3–3·2)
Age at diagnosis, 
median (IQR) (years)





Time before diagnosis, 
median (IQR) 
(months)
53 (22–79) 6 (2–19)
T1D = type 1 diabetes; IQR = interquartile range; n.a. = not available.
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(APC) (Life Technologies, Carlsbad, CA, USA) to monomeric 
pHLA at a molar streptavidin  :  pHLA ratio of 1  :  4. 
Phosphate-buffered saline (PBS) was added to give a final 
multimer concentration of 0·1 mg/ml pHLA content. Tetram-
ers were stored in the dark at 4°C and used on the same 
day as assembly.
Cell staining and flow cytometry
Thawed peripheral blood mononuclear cells (PBMC) were 
washed in RPMI supplemented with 2% human AB serum; 
3–4  million PBMCs per stain were transferred to flow 
cytometry tubes, washed with PBS and stained with a 
live/dead aqua amine reactive dye (Invitrogen, Carlsbad, 
CA, USA) for 10  min at room temperature, followed by 
washing with PBS. PBMCs were incubated with the pro-
tein kinase inhibitor dasatinib (Axon Medchem, Reston, 
VA, USA) at a final concentration of 50  nM for 30  min 
at 37°C to enhance the detection of low-avidity T cells 
[12,54] and C-C chemokine receptor type 7 (CCR7) BV421 
monoclonal antibody (Biolegend, San Diego, CA, USA). 
Subsequently, PBMCs were stained for 10  min at 37°C 
with 1 μg of pHLA tetramer per tube. After washing with 
fluorescence activated cell sorter (FACS) buffer (PBS sup-
plemented with 2% human AB serum and 3% fetal calf 
serum), PBMCs were stained with mouse anti-APC uncon-
jugated monoclonal antibody (Biolegend) at a concentra-
tion of 10  mg/ml on ice for 20  min to stabilize binding 
of APC-labelled tetramers [55]. After washing with FACS 
buffer, cells were stained with the following surface mon-
oclonal antibodies/fluorophores for 20  min on ice: CD3 
BV785, CD8 phycoerythrin cyanin 7 (PECy7), CD27 BV605 
(all Biolegend); CD14 V500, CD16 V500, CD19 V500, 
CD45RA PE-CF594, CD95 PE, CD57 fluorescein isothio-
cyanate (FITC) (all BD Biosciences, San Jose, CA, USA) 
and CD4 PECy5.5 (Invitrogen). Stained PBMCs were kept 
on ice and in the dark until acquisition on the same day 
on an LSR Fortessa (BD Biosciences). Gates to define 
tetramer positivity were set based on PBMC samples which 
were not stained with tetramer. No CD8 T cells were 
stained in the absence of tetramers. We elected to use 
this method to define tetramer-positive cells as control 
tetramers incorporating irrelevant self-peptides are likely 
to stain some T cells, while control tetramers incorporat-
ing foreign peptides from previously unencountered viruses 
have been found to stain some T cells in seronegative 
donors [56]. Within the antigen-specific CD8 T cell pop-
ulations and total CD8 T cell populations, CD8 T cell 
subsets were assessed using the following cell surface marker 
combinations: naive (N;CCR7+CD45RA+CD27+CD57–
CD95–), stem-cell memory-like (SCM; CCR7+CD45RA+ 
CD27+CD57–CD95+), central memory (CM; CCR7+ 
CD45RA–CD27+), transitional memory (TM; CCR7–
CD45RA–CD27+), effector memory (EM; CCR7–CD45RA–
CD27–), terminal effector (TE; CCR7–CD45RA+). The 
gating strategy is illustrated in Supporting information, 
Fig. S1. Flow cytometry data were analysed using FlowJo 
version 9.4 (Tree Star, Ashland, OR, USA). Due to limita-
tions in cell numbers available of some samples, tetramer 
staining was limited as follows: two HLA-B*3906+ control 
subjects were not stained with EBV tetramer; two HLA-
A*2402+ control subjects, six HLA-A*2402+ prediagnosis 
subjects and five HLA-A*2402+ pre-seroconversion subjects 
were not stained with InsB tetramer.
Dual-colour tetramer staining
Dual-colour staining was performed with the newly devel-
oped pHLA-B*3906 tetramers to verify the specificity of 
tetramer-binding cells (Supporting information, Fig. S2). 
The pHLA-B*3906 tetramers manufactured with PPI5–12 
and EBV BMRF1268–276 were assembled over five separate 
20-min steps with the successive addition of streptavi-
din–APC or streptavidin–PE (both Life Technologies) to 
monomeric pHLA at a molar streptavidin  :  pHLA ratio 
of 1  :  4. PBS was added to give a final multimer con-
centration of 0·1  mg/ml pHLA content. Thawed PBMC 
were stained as described above.
Statistics
Comparisons between subject groups were performed using 
non-parametric Mann–Whitney U-tests. Paired compari-
sons between groups were performed using the non-
parametric Wilcoxon paired test. Statistical analysis was 
performed using GraphPad Prism version 7.0e.
Results
HLA-B*3906-restricted autoreactive CD8+ T cells in 
type 1 diabetes
As HLA-B*39 carries the strongest type 1 diabetes risk 
of all HLA class I gene polymorphisms, we sought to 
determine whether HLA-B*39-restricted CD8+ T cells 
with specificity for β cell antigens could be detected in 
individuals with type 1 diabetes. In particular, we exam-
ined HLA-B*3906-restricted CD8+ T cells specific for 
Table 4. HLA-B*3906 and HLA-A*2402-restricted CD8 T cell epitopes
Epitope





EBV BMRF1268–276 B*3906 YRSGIIAVV
PPI = preproinsulin; HLA = human leucocyte antigen; EBV = Epstein–
Barr virus.
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the preproinsulin epitope PPI5–12 by staining ex-vivo 
PBMC samples with pHLA class I tetramers. As a con-
trol, we analysed CD8+ T cells specific for the HLA-
B*3906-restricted EBV lytic cycle protein epitope 
BMRF1268–276. We assessed the frequency and phenotype 
of antigen-specific CD8+ T cells in PBMC samples 
obtained within 10  days of type 1 diabetes diagnosis 
from children aged up to 5 years and in non-diabetic, 
age-matched and HLA-matched control subjects (Table 1). 
Two subjects with type 1 diabetes and one control sub-
ject tested positive for EBV antibodies (data from these 
subjects are highlighted in Supporting information, 
Fig. S3). Representative tetramer staining is shown in 
Fig. 1a. The frequency of PPI5–12-specific and EBV 
BMRF1268–276-specific CD8+ T cells was found to be 
similar in type 1 diabetes subjects and control subjects 
(Fig. 1b). Phenotypical analysis revealed that in subjects 
with type 1 diabetes there was a higher percentage of 
PPI5–12-specific transitional memory CD8+ T cells com-
pared to control subjects (Fig. 1c). In contrast, no sig-
nificant differences were observed in the phenotype of 
EBV BMRF1268–276-specific CD8+ T cells in subjects with 
type 1 diabetes compared to control subjects (Fig. 1c). 
The median percentages of naïve, memory and terminal 
effector cells comprising the PPI5–12- and EBV BMRF1268–276- 
specific CD8+ T cell populations are represented in 
Fig. 1d. The pie charts illustrate the higher percentage 
of PPI5–12-specific memory CD8+ T cells in subjects with 
type 1 diabetes compared to control subjects and the 
similarity in the percentages of EBV BMRF1268–276-specific 
CD8+ T cell subsets in subjects with type 1 diabetes 
and control subjects (Fig. 1d).
In order to determine whether distinctive phenotypical 
characteristics were present in the antigen-specific CD8+ 
T cells, we compared their phenotypes with those found 
in the polyclonal CD8+ T cell population within each 
PBMC sample. We used spider plots to visualize the dif-
ference in the memory and effector T cell subsets com-
prising the PPI5–12-specific, EBV BMRF1268–276-specific and 
polyclonal CD8+ T cell populations in subjects with type 
1 diabetes and control subjects (Fig. 1e). For example, in 
subjects with type 1 diabetes, we observe a larger propor-
tion of memory T cell subsets in the PPI5–12-specific CD8+ 
T cell population compared to the polyclonal CD8+ T 
cell population, illustrated by a red polygon (representing 
PPI-specific T cells) that is more expanded along the arcs 
of the web compared to the blue polygon (representing 
polyclonal CD8+ T cells) (Fig. 1e). Paired comparisons of 
tetramer-specific and polyclonal CD8+ T cells revealed 
that in subjects with type 1 diabetes, the PPI5–12-specific 
CD8+ T cell population was comprised of significantly 
fewer naive cells and significantly more stem-cell-like 
memory cells, central memory cells and transitional mem-
ory cells compared to the polyclonal CD8+ T cell 
population (Fig. 1f). Therefore, the PPI5–12-specific CD8+ 
T cells display a more antigen-experienced phenotype 
compared to polyclonal CD8+ T cells in type 1 diabetes 
subjects. Importantly, these differences were not observed 
within the PPI5–12-specific CD8+ T cell population in con-
trol subjects, indicating that autoreactive T cells acquire 
this phenotype as a result of the disease process (Fig. 1f). 
In EBV-specific CD8+ T cell populations, there was an 
increase in stem cell memory-like and central memory 
cells compared to the polyclonal CD8+ T cell population 
in type 1 diabetes subjects, and we did not detect sig-
nificant phenotypical differences compared to polyclonal 
CD8+ T cells in control subjects (Fig. 1f). The phenotype 
of polyclonal CD8+ T cells was not significantly different 
between type 1 diabetes subjects and control subjects 
(Supporting information, Fig. S4). A comparison of the 
data from the autoantibody-positive and -negative control 
subjects is shown in Supporting information, Fig. S5.
Additionally, we had the opportunity to assess PPI5–12-
specific CD8+ T cells 5  years prior to the diagnosis of 
type 1 diabetes in an HLA-B*3906+ child who was aged 
3·3 years at the time of blood draw (Supporting informa-
tion, Fig. S6a). In this individual, we observed a higher 
frequency of PPI5–12-specific transitional memory CD8+ T 
cells compared to control subjects, as we observed in 
patients with type 1 diabetes (Supporting information, Fig. 
S6b). Compared to the polyclonal CD8+ T cell population, 
in the PPI5–12-specific CD8+ T cell population we observed 
fewer naive cells and more central memory cells, transi-
tional memory cells, effector memory cells and terminal 
effector cells, indicative of an antigen-experienced phenotype 
(Supporting information, Fig. S6c,d). Although we were 
not able to compare samples from this case before and 
after diagnosis, the phenotypical characteristics of PPI5–12-
specific CD8+ T cells in the subject sampled 5 years before 
diagnosis appear to be similar to the HLA-B*3906+ subjects 
sampled at the time of diagnosis of type 1 diabetes.
HLA-A*2402-restricted autoreactive CD8+ T cells in 
type 1 diabetes
Using a similar approach, we studied CD8+ T cells recog-
nizing β cell peptides presented by HLA-A*2402 in children 
followed from birth to clinical diagnosis. PPI3–11- and 
InsB15–24-specific pHLA tetramers were used to stain PBMCs 
from 15  children ascertained before clinical diagnosis and 
15  age-, sex- and HLA-matched control subjects (Fig. 2a). 
We found that the frequencies of circulating PPI3–11- and 
InsB15–24-specific CD8+ T cells were similar in subjects with 
type 1 diabetes and control subjects (Fig. 2b), and the 
subject groups did not differ significantly in terms of the 
phenotype of PPI3–11- or InsB15–-24-specific CD8+ T cells 
(Fig. 2c,d). However, when antigen-specific and polyclonal 
CD8+ T cell populations were compared, PPI3–11- and 
InsB15–24-specific CD8+ T cell populations in type 1 diabetes 
L. Yeo et al.
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Fig. 1. Frequency and phenotype of human leucocyte antigen (HLA)-B*3906-restricted preproinsulin (PPI)- and Epstein–Barr virus (EBV)-specific 
CD8+ T cells in patients with newly diagnosed type 1 diabetes and control subjects. (a) Representative tetramer staining of peripheral blood 
mononuclear cells (PBMC) from type 1 diabetes (T1D) subjects (n = 10) and controls (n = 7). (b) Frequency of PPI5–12- and EBV BMRF1268–276-specific 
CD8+ T cells. Mann–Whitney U-tests P > 0·05. (c) Phenotype of PPI5–12- and EBV BMRF1268–276-specific CD8+ T cells. Mann–Whitney U-tests; 
*P < 0·05. (d) Median T cell subset percentages for PPI5–12- and EBV BMRF1268–276-specific CD8+ T cells in T1D and controls. Memory: pooled stem 
cell-like memory, central memory, transitional memory and effector memory. (e) Frequency of memory and effector T cell subsets expressed as a 
percentage of non-naive T cells within tetramer-specific (red) and polyclonal (blue) CD8+ T cell populations. Radial lines represent intervals of T cell 
subset frequencies of 10% from 0 to 60%, with the lowest value at the centre and the highest value at the periphery. Polygons link the frequency of each 
T cell subset. (f) Phenotype of PPI5–12- and EBV BMRF1268–276-specific CD8+ T cells (circles) compared to polyclonal CD8+ T cells (squares). Wilcoxon 
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and control subjects contained significantly fewer naive 
cells and significantly more stem cell-like memory, central 
memory and transitional memory cells compared to poly-
clonal CD8+ T cell populations (Fig. 2e,f). In addition, 
PPI3–11-specific T cell populations also contained significantly 
more effector memory cells than polyclonal CD8+ T cell 
populations (Fig. 2f). The phenotype of polyclonal CD8+ 
T cells was not significantly different between type 1 dia-
betes subjects and control subjects (Supporting information, 
Fig. S7). Therefore, PPI3–11- and InsB15–24-specific CD8+ T 
cells in both subject groups showed a more antigen-expe-
rienced phenotype compared to polyclonal CD8+ T cells.
In order to evaluate changes in autoreactive HLA-
A*2402-restricted CD8+ T cell populations before and after 
the initiation of islet autoimmunity, we analysed the fre-
quency and phenotype of β cell-specific CD8+ T cells in 
longitudinal samples from 11 HLA-A*2402+ children ascer-
tained before seroconversion to autoantibody positivity 
(median  =  5 months) compared to samples taken before 
clinical diagnosis after the appearance of autoantibodies 
(median  =  2  months before diagnosis) (Table 4, Fig. 3a). 
The frequencies of PPI3–11- and InsB15–24-specific CD8+ T 
cells were not found to be significantly different in the 
samples taken before and after seroconversion (Fig. 3b). 
When we compared the phenotype of PPI3–11-specific CD8+ 
T cells before seroconversion and before diagnosis, we 
found it was similar (Fig. 3c,d). However, within the 
InsB15–24-specific CD8+ T cell population, we observed that 
the percentage of terminal effector cells was increased 
and the percentage of central memory cells was decreased 
in samples taken after seroconversion relative to samples 
taken before seroconversion (Fig. 3c,e). In contrast, the 
phenotype of the polyclonal CD8+ T cell population 
remained similar in pre- and post-seroconversion samples 
(Fig. 3e). Collectively, these results provide evidence that 
β cell-reactive CD8+ T cells restricted by disease-associated 
HLA class I molecules display an antigen-experienced 
phenotype and acquire enhanced effector function during 
the period leading to clinical diagnosis.
Discussion
The HLA class I HLA-B*39 allele confers the strongest 
risk of type 1 diabetes of all HLA class I gene polymor-
phisms [17]. This is the first study to report autoreactive 
CD8+ T cells restricted by HLA-B*3906 in blood samples 
from individuals with type 1 diabetes. Here we show that 
the transitional memory subset of B*3906-restricted PPI-
specific transitional memory CD8+ T cells comprises a 
higher proportion of the total PPI-specific population in 
HLA-B*3906+ children with new-onset type 1 diabetes 
compared to HLA-matched control subjects. Transitional 
memory cells have a differentiation status that is inter-
mediate between that of central memory cells and effector 
memory cells in terms of phenotype, transcription factor 
expression and cytokine-induced proliferation [57–59]. 
According to the recently proposed model of progressive 
differentiation, a naive T cell will differentiate gradually 
to different memory subsets through stem cell-like memory, 
central memory, transitional memory, effector memory and 
terminal effector, progressively losing or acquiring specific 
functions [60]. Central memory cells home to secondary 
lymph nodes and are better equipped to persist and pro-
liferate in response to antigen, whereas effector memory 
cells are more cytolytic and express integrins and chemokine 
receptors that facilitate their entry into inflamed tissues 
[61]. So far, a distinct pathophysiological role for the 
intermediate transitional memory subset has not been 
described. Here we defined transitional memory cells as 
having a cell surface expression marker profile of CCR7–
CD45RA–CD27+, where the absence of CCR7 expression 
suggests that these cells have been activated in lymph 
nodes and are capable of homing to inflamed islets. Studies 
in non-human primates have reported that transitional 
memory CD8+ T cells have higher expression levels of 
the transcription factors eomesodermin (EOMES), aryl 
hydrocarbon receptor (AHR) and RAR-related orphan 
receptor C (RORC) compared to central memory and 
effector memory cells [57]. The major role of EOMES is 
to maintain a memory CD8+ T cell repertoire capable of 
expansion on re-encountering antigen. EOMES also func-
tions as a master regulator of cell-mediated immunity 
that controls genes encoding effector molecules including 
IFN-γ, granzyme B and perforin [62–64]. This would 
indicate that, like effector memory cells, transitional mem-
ory cells are able to execute target cell killing. As far as 
we know, a role for antigen-specific transitional memory 
CD8+ T cells in autoimmune pathology has not yet been 
described. However, the capability of transitional memory 
cells to home to tissues and mediate cytotoxic effector 
functions suggests that the higher frequency of PPI5–12-
specific transitional memory cells we have detected in 
patients affected by type 1 diabetes has the potential to 
directly mediate β cell killing.
Further observations were made by pairwise comparison 
of functional phenotypes of HLA-B*3906-restricted PPI5–12-
specific CD8+ T cell populations with those of polyclonal 
CD8+ T cells, the latter representing a synthesis of all 
CD8+ T cell-mediated antigen experiences in each subject. 
The aim of these analyses was to identify functional phe-
notypes specifically expanded by autoantigens. We noted 
that multiple memory T cell subsets were enriched within 
PPI5–12-specific CD8+ T cell populations in multiple mem-
ory T cell subsets in children with type 1 diabetes, but 
this was not observed in non-diabetic control subjects. 
An increase in PPI5–12-specific stem cell-like memory cells, 
central memory cells and transitional memory cells was 
accompanied by a reduction in naive cells compared to 
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Fig. 2. Frequency and phenotype of human leucocyte antigen (HLA)-A*2402-restricted preproinsulin (PPI)- and insulin B (InsB)-specific CD8+ T 
cells before the diagnosis of type 1 diabetes (T1D) in affected subjects and control subjects. (a) Representative tetramer staining of peripheral blood 
mononuclear cells (PBMC) from subjects before T1D diagnosis (n = 17) and controls (n = 17). (b) Frequency of PPI3–11 and InsB15–24-specific CD8+ T 
cells. Mann–Whitney U-tests P > 0·05. (c) Phenotype of PPI3–11 and InsB15–24-specific CD8+ T cells. (d) Median T cell subset percentages for PPI3–11 and 
InsB15–24-specific CD8+ T cells. Memory: pooled stem cell-like memory, central memory, transitional memory and effector memory. (e) Frequency of 
memory and effector T cell subsets expressed as a percentage of non-naive T cells within tetramer-specific (red) and polyclonal (blue) CD8+ T cell 
populations. Radial lines represent intervals of T cell subset frequencies of 5% from 0 to 35%, with the lowest value at the centre and the highest value 
at the periphery. Polygons link the frequency of each T cell subset. (f) Phenotype of tetramer-specific CD8+ T cells (squares) compared to polyclonal 
CD8+ T cells (circle). Wilcoxon paired tests *P < 0·05, **P < 0·01, ***P < 0·001. Abbreviations: SCM: stem cell-like memory, CM: central memory; TM: 
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the polyclonal CD8+ T cell population. Memory CD8+ T 
cells are poised for rapid proliferative responses, and to 
execute cytotoxic functions and secrete effector cytokines 
upon re-encountering their cognate antigen [61,65–67]. 
Therefore, the enrichment of β cell-specific memory CD8+ 
T cell populations at the time of clinical diagnosis indi-
cates that newly diagnosed type 1 diabetes is characterized 
by antigen-driven differentiation of HLA-B*3906-restricted 
CD8+ T cells, probably facilitated by a tissue-specific 
inflammatory process. Collectively, our findings suggest 
that enrichment of PPI5–12-specific memory CD8+ T cell 
subsets in subjects with type 1 diabetes compared to non-
diabetic control subjects and polyclonal CD8+ T cells may 
reflect a driver role in relation to β cell killing, consistent 
with the accelerated loss of β cells that has been observed 
in HLA-B*3906+ individuals, relative to patients with other 
HLA class I alleles [17,20–24]. HLA-B*3906 is also known 
to associate with a relatively younger age of diagnosis 
and notably, this allele has been reported to be more 
frequent in children who progress to clinical type 1 dia-
betes under the age of 5·5 years [20], an age group which 
corresponds with the cohort examined in this study.
Clinical diagnosis of type 1 diabetes is an event mark-
ing the late stages of the destructive autoimmune process, 
when the number of functional β cells falls below the 
threshold required for adequate insulin production. 
However, the first signs of autoimmunity emerge months 
or years earlier with the appearance of several islet-specific 
autoantibodies. In longitudinal samples from HLA-A*2402+ 
children with high-risk HLA class II genotypes, we found 
that CD8+ T cells specific for InsB15–24 had reduced fre-
quencies of central memory cells and elevated frequencies 
of terminal effectors before diagnosis, relative to early-stage 
disease before the appearance of autoantibodies. The per-
centage of terminal effector cells within total CD8+ T cell 
populations was within the range previously reported for 
children of a similar age [68–71]. Surprisingly, we observed 
phenotypical changes in CD8+ T cells with specificity for 
InsB15–24 but not PPI3–11. We speculate that InsB presenta-
tion may be enhanced by autoantibody-mediated antigen 
presentation which will increase after seroconversion, 
whereas PPI, not being a part of mature insulin/proinsulin, 
may be targeted later by the autoimmune response via 
epitope spreading. While the concept of epitope spreading 
of autoantibody responses in preclinical type 1 diabetes 
has been well established [72–77], intermolecular spreading 
of T cell responses has also been described during the 
preclinical period of type 1 diabetes [78,79] and in animal 
models of diabetes [80–83].
It is important to note that as none of the subjects 
examined in this study had received exogenous insulin, 
the changes we observed in InsB-specific CD8+ T cells 
reflect the natural history of disease. Our results suggest 
that the natural evolution of the β cell-specific CD8+ T 
cell response during the prediabetic period in young chil-
dren becomes increasingly dominated by end-stage cytolytic 
effector cells which are capable of directly mediating β 
cell destruction. These data fit with observations that at 
clinical diagnosis β cell destruction is already well advanced 
[84]. Of interest, previous studies of the DIPP cohort 
have reported that the HLA-A*24 allele is associated with 
accelerated disease progression from seroconversion to 
clinical disease [26]. One interpretation is that HLA-A*24-
restricted CD8+ T cells are potent mediators of β cell 
death after autoimmunity has been established. 
Furthermore, the presence of the HLA-A*24 allele has 
also been associated with a reduced frequency of particular 
autoantibodies at clinical diagnosis [85–87]. To explain 
this effect, it has been suggested that compared to other 
allotypes, HLA-A*24-restricted CD8+ T cells may mediate 
a more complete β cell destruction, resulting in a loss of 
antigenic stimulus, or alternatively, HLA-A*24-restricted 
CD8+ T cells may mediate a more rapid β cell destruc-
tion, thus attenuating inter- and intramolecular spreading 
of the autoimmune response [85–87]. Our previous work 
showed that HLA-A*2402-restricted PPI-specific CD8+ T 
cell clones derived from patients with type 1 diabetes are 
able to kill isolated β cells in vitro, exemplifying the poten-
tial for such cells to directly mediate β cell death in 
individuals with type 1 diabetes [88].
In this study, we observed that β cell-specific CD8+ T 
cell frequencies in peripheral blood were similar in subjects 
with type 1 diabetes and control subjects. Similarly, other 
studies have found no significant differences between type 
1 diabetes subjects and healthy donors in the frequencies 
of circulating CD8+ T cells reactive to multiple HLA-A2-
restricted β cell epitopes [12,56,89]. However, some studies 
have reported higher frequencies of β cell-reactive CD8+ 
T cells in HLA-A*02+ or HLA-A*24+ type 1 diabetes sub-
jects compared to healthy donors [13,89–91], and it is 
important to take into account differences in methods 
(such as dasatinib enhancement of tetramer staining) and 
study populations (i.e. adults versus children).
In summary, we have demonstrated that cytotoxic T 
cells restricted by disease-associated HLA class I molecules 
display an antigen-experienced phenotype and acquire 
enhanced effector function during the period leading to 
clinical diagnosis, suggesting that these cells have a critical 
role in driving β cell destruction and may provide useful 
biomarkers of disease activity in monitoring progression 
to type 1 diabetes.
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Fig. 3. Frequency and phenotype of human leucocyte antigen (HLA)-A*2402-restricted preproinsulin (PPI)3–11- and InsB15–24-specific CD8+ T cells 
before and after seroconversion to autoantibody positivity. (a) Representative tetramer staining of longitudinal peripheral blood mononuclear cells 
(PBMC) samples (n = 11). (b) Frequency of PPI3–11 and InsB15–24-specific CD8+ T cells. Wilcoxon paired tests were used to compare groups (P > 0·05). 
(c) Median T cell subset percentages for PPI3–11 and InsB15–24-specific CD8+ T cells. Memory: pooled stem cell-like memory, central memory, 
transitional memory and effector memory. (d) Phenotype of PPI3–11-specific and polyclonal CD8+ T cells. Wilcoxon paired tests were used for 
comparisons (P > 0·05). (e) Phenotype of InsB15–24-specific and polyclonal CD8+ T cells. Wilcoxon paired tests were used for comparisons; *P < 0·05. 
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Supporting Information
Additional supporting information may be found in the on-
line version of this article at the publisher’s web site:
Fig. S1. Flow cytometry gating strategy for determination 
of antigen-specific CD8 T cell subsets. (a) Lymphocytes 
were defined as CD3 positive, ‘Dump’ (dead cell stain, 
CD14, CD16, CD19) negative gated on FSC and SSC char-
acteristics. Doublets and CD4+CD8+ double-positive cells 
were excluded. Cells were gated as CD8+Tetramer+ or 
CD8+Tetramer-. (b) Gating of CD8+ T cell subsets: Naïve 
(N;CCR7+CD45RA+CD27+CD57-CD95-), stem cell mem-
ory-like (SCM; CCR7+CD45RA+CD27+CD57-CD95+), cen-
tral memory (CM; CCR7+CD45RA-CD27+), transitional 
memory (TM; CCR7-CD45RA-CD27+), effector memory 
(EM; CCR7-CD45RA-CD27-) and terminal effector (TE; 
CCR7-CD45RA+). (c) Schematic of the CD8+ T cell sub-
sets analysed and the cell surface markers used for their 
definition.
Fig. S2. Dual-colour tetramer staining with pHLA-B*3906 
tetramers loaded with PPI5-12 and EBV BMRF1268-276. (a) 
Gating strategy used to identify double-positive tetram-
er-binding CD8+ T cells. Lymphocytes were defined as CD3+, 
‘Dump’ (dead cell stain, CD14, CD16, CD19)-negative, and 
gated on lymphocyte SSC and FSC characteristics. Doublets 
were excluded. (b) PBMC from an HLA-B*3906+ donor 
stained with PPI5-12 and EBV BMRF1268-276 pHLA-B*3906 
tetramers which were dual-labelled with APC and PE. The 
majority of tetramer-binding cells are double-positive for 
both tetramers.
Fig. S3. Frequency and phenotype of HLA-B*3906-
restricted EBV-specific CD8+ T cells in EBV antibody-pos-
itive (n  =  3) and antibody-negative (n  =  9) subjects. (a) 
Frequency of EBV BMRF1268-276-specific CD8+ T cells in 
EBV antibody-positive (red) and antibody-negative (white) 
subjects. (b) Phenotype of EBV BMRF1268-276-specific CD8+ 
T cells in EBV antibody-positive (red) and antibody-nega-
tive (white) subjects.
Fig. S4. Phenotype of polyclonal CD8+ T cell popula-
tions in HLA-B*3906+ newly diagnosed type 1 diabetes 
subjects and HLA-B*3906+ control subjects. The pheno-
type of polyclonal CD8+ T cells was not found to be sig-
nificantly different between HLA-B*3906+ T1D subjects 
(grey) and healthy controls (white). Mann–Whitney U-tests 
P > 0·05.
Autoreactive diabetogenic T cells restricted by high-risk class I HLA
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Fig. S5. Frequency and phenotype of HLA-B*3906-
restricted PPI-specific CD8+ T cells in autoantibody 
positive control (n = 1) and negative controls (n = 6). (a) 
Frequency and phenotype of PPI5-12-specific CD8+ T cells 
and polyclonal CD8+ T cells from autoantibody-negative 
controls (white), autoantibody-positive control (red) and 
T1D subjects (black). (b) Frequency and phenotype of EBV 
BMRF1268-276-specific CD8+ T cells and polyclonal CD8+ T 
cells from autoantibody-negative controls (white), autoanti-
body-positive control (red) and T1D subjects (black).
Fig. S6. Frequency and phenotype of HLA-B*3906-
restricted PPI-specific CD8+ T cells before the diagnosis 
of type 1 diabetes. (a) Frequency of PPI5-12-specific CD8+ 
T cells from an HLA-B*3906+ type 1 diabetes subject before 
diagnosis (black) compared to HLA-B*3906+ newly diag-
nosed type 1 diabetes subjects (grey) and HLA-B*3906+ 
control subjects (white). (b) Phenotype of PPI3-11-specific 
CD8+ T cells from an HLA-B*3906+ type 1 diabetes sub-
ject before diagnosis (black) compared to HLA-B*3906+ 
newly diagnosed type 1 diabetes subjects (grey) and 
HLA-B*3906+ control subjects (white). (c) Frequency of 
memory and effector T cell subsets expressed as a percent-
age of non-naïve T cells within tetramer-specific (red) and 
polyclonal (blue) CD8+ T cell populations. Radial lines 
represent intervals of T cell subset frequencies of 10% 
from 0 to 50%, with the lowest value at the centre and the 
highest value at the periphery. Polygons link the frequency 
of each T cell subset. (d) Phenotype of PPI5-12-specific 
CD8+ T cells (squares) compared to total polyclonal CD8+ 
T cells (circles) in an HLA-B*3906+ type 1 diabetes subject 
before diagnosis (black), HLA-B*3906+ newly diagnosed 
type 1 diabetes subjects (grey) and HLA-B*3906+ control 
subjects (white).
Fig. S7. Phenotype of polyclonal CD8+ T cell populations 
in HLA-A*2402+ type 1 diabetes subjects before diagno-
sis and HLA-A*2402+ control subjects. The phenotype of 
polyclonal CD8+ T cells was not found to be significantly 
different between HLA-A*2402+ pre-diagnosis subjects 
(grey) and healthy controls (white). Mann–Whitney U-tests 
P > 0.05.
